在FDA同意评估状细胞疾病中使用mitapivat的较短试验后,Agios股票激增. Agios stock surged after FDA agreed to evaluate a shorter trial for mitapivat in sickle cell disease.

在FDA会议上,监管机构同意评估状细胞疾病中使用mitapivat的较短确认试验后,Agios药品股价大幅升. Agios Pharmaceuticals stock surged following an FDA meeting where regulators agreed to evaluate a shorter confirmatory trial for mitapivat in sickle cell disease. 该公司计划根据血红蛋白阳性数据提交补充申请, 要求加速批准药物, 以扩大该药物的价值达到数十亿美元的市场. The company plans to submit a supplemental application for accelerated approval based on positive hemoglobin data, aiming to expand the drug into a multi-billion dollar market.